Status: Not yet recruiting
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.
Participants needed: 56
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Runshi Pharmaceutical Technology Co., LtdUpdated: Dec 18, 2024
Eligibility criteria
Aged >= 18 years; [+5]
Patients who are known or suspected to be allergic to the test drug or its compo... [+19]